[go: up one dir, main page]

WO2006125651A3 - Nouvelle utilisation de composes organiques - Google Patents

Nouvelle utilisation de composes organiques Download PDF

Info

Publication number
WO2006125651A3
WO2006125651A3 PCT/EP2006/005005 EP2006005005W WO2006125651A3 WO 2006125651 A3 WO2006125651 A3 WO 2006125651A3 EP 2006005005 W EP2006005005 W EP 2006005005W WO 2006125651 A3 WO2006125651 A3 WO 2006125651A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
treatment
hydroxyl
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/005005
Other languages
English (en)
Other versions
WO2006125651A2 (fr
Inventor
Ann Fowler
Daniel Raederstorff
Goede Schueler
Joseph Schwager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to CN2006800182412A priority Critical patent/CN101184484B/zh
Priority to AT06753874T priority patent/ATE529107T1/de
Priority to EP06753874A priority patent/EP1937250B1/fr
Priority to ES06753874T priority patent/ES2375302T3/es
Priority to US11/920,346 priority patent/US20090176873A1/en
Priority to JP2008512773A priority patent/JP2008542226A/ja
Publication of WO2006125651A2 publication Critical patent/WO2006125651A2/fr
Publication of WO2006125651A3 publication Critical patent/WO2006125651A3/fr
Anticipated expiration legal-status Critical
Priority to US12/801,646 priority patent/US20100298427A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I) dans laquelle la ligne pointillée est une liaison facultative; R1 est butyle ou butyryle si R2 est hydroxyle mais butyle si R2 est hydrogène; ou R1 et R2 pris ensemble sont 1-butylidène éventuellement substitué par hydroxyle, méthyle, ou 3-(a,ß-diméthylacrylyloxy)-pentylidényle; X est groupe fonctionnel choisi dans le groupe des X1, X2, X3, X4, et X5; X étant X2, X3 ou X5 si la ligne pointillée dans la formule (I) est absente et X1, X4 ou X5 si la ligne pointillée signifie une liaison dans la formule (I) ci-dessus; R3 est hydroxyle ou butyryle; et n vaut 1 ou 2, et leur utilisation comme agents actifs dans la prévention, la lutte contre, et le traitement d'état nécessitant la modulation de l'inflammation chez des mammifères. Dans l'autres aspect, l'invention concerne l'utilisation des composés de l'invention comme agents actifs pour la fabrication de médicaments et compositions destinés à la prévention, la lutte contre et le traitement d'états nécessitant la modulation de l'inflammation. Les composés représentés par la formule (I) tels que définis ci-dessus, peuvent également convenir (à la fabrication d'une composition) pour la gestion de la douleur, de la fièvre et des lésions, particulièrement les lésions sportives. En outre, les composés représentés par la formule (I) tels que définis ci-dessus, peuvent également convenir (à la fabrication d'une composition) pour la préservation et la régénération du cartilage articulaire.
PCT/EP2006/005005 2005-05-24 2006-05-24 Nouvelle utilisation de composes organiques Ceased WO2006125651A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2006800182412A CN101184484B (zh) 2005-05-24 2006-05-24 用于治疗炎性失调的藁本内酯衍生物
AT06753874T ATE529107T1 (de) 2005-05-24 2006-05-24 Ligustilid-derivate zur behandlung von entzündungserkrankungen
EP06753874A EP1937250B1 (fr) 2005-05-24 2006-05-24 Derives de ligustilide pour le traitement de maladies inflammatoires
ES06753874T ES2375302T3 (es) 2005-05-24 2006-05-24 Derivados de ligustilida para el tratamiento de trastornos inflamatorios.
US11/920,346 US20090176873A1 (en) 2005-05-24 2006-05-24 Novel use of organic compounds
JP2008512773A JP2008542226A (ja) 2005-05-24 2006-05-24 炎症性障害の治療のためのリグスチリド誘導体
US12/801,646 US20100298427A1 (en) 2005-05-24 2010-06-18 Anti-inflammatory compositions and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011203.6 2005-05-24
EP05011203 2005-05-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/801,646 Division US20100298427A1 (en) 2005-05-24 2010-06-18 Anti-inflammatory compositions and their use

Publications (2)

Publication Number Publication Date
WO2006125651A2 WO2006125651A2 (fr) 2006-11-30
WO2006125651A3 true WO2006125651A3 (fr) 2007-07-19

Family

ID=37054238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005005 Ceased WO2006125651A2 (fr) 2005-05-24 2006-05-24 Nouvelle utilisation de composes organiques

Country Status (8)

Country Link
US (2) US20090176873A1 (fr)
EP (1) EP1937250B1 (fr)
JP (1) JP2008542226A (fr)
KR (1) KR20080015802A (fr)
CN (1) CN101184484B (fr)
AT (1) ATE529107T1 (fr)
ES (1) ES2375302T3 (fr)
WO (1) WO2006125651A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006581A2 (fr) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Nouvelles compositions
KR20090033470A (ko) * 2006-07-14 2009-04-03 디에스엠 아이피 어셋츠 비.브이. 로즈힙 및 다른 활성 약품을 포함하는, 염증성 질환의 치료를 위한 조성물
WO2008006582A1 (fr) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprenant du magnolol ou de l'honokiol et d'autres agents actifs pour le traitement de maladies inflammatoires
CN101991568B (zh) * 2009-08-12 2012-02-08 上海张江中药现代制剂技术工程研究中心 洋川芎内酯i在制备抗抑郁症药物、偏头痛药物及其他5-羟色胺能系统相关疾病药物中的应用
CA2781233A1 (fr) * 2009-11-23 2011-06-16 Purapharm International (Hk) Limited Utilisation des lactones extraites de lingusticum chuanxiong dans le traitement des troubles inflammatoires et immunomodules
CN102125548A (zh) * 2010-01-13 2011-07-20 石药集团恩必普药业有限公司 丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用
US8927601B2 (en) * 2011-12-20 2015-01-06 National Dong Hwa University Uses of N-butylidenephthalide in treating a liver injury and improving liver function
TWI460168B (zh) * 2012-08-10 2014-11-11 Univ China Medical 用於抑制運動神經元自體吞噬之醫藥組合物及其應用
JP6178802B2 (ja) * 2012-08-17 2017-08-09 中國醫藥大學 運動ニューロンのオートファジーを阻害するための医薬組成物およびその使用
CN102793696B (zh) * 2012-08-31 2014-09-10 甘肃中医学院 丁苯酞在制备治疗支气管哮喘药物中的应用
US20140271568A1 (en) 2013-03-12 2014-09-18 Hawking Biological Technology Co., Ltd Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
TWI487521B (zh) * 2013-03-12 2015-06-11 Hawking Biolog Technology Co Ltd 苯酞化合物之應用
TWI511727B (zh) 2014-07-02 2015-12-11 Everfront Biotech Inc 苯酞化合物之應用
CN112451519A (zh) * 2014-07-28 2021-03-09 长弘生物科技股份有限公司 丁烯基苯酞的用途及将其制备为医药组合物的方法
US10682335B2 (en) * 2014-07-28 2020-06-16 Everfront Biotech Inc. Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same
CN106795490B (zh) * 2014-09-11 2021-01-19 台湾粒线体应用技术股份有限公司 用线粒体特化细胞治疗神经退行性疾病的医药组合物
US10463645B2 (en) * 2016-05-19 2019-11-05 Everfront Biotech Inc. Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis
JP6824287B2 (ja) * 2016-05-23 2021-02-03 長弘生物科技股▲ふん▼有限公司 自己免疫系の活性化におけるｚ−ブチリデンフタリドの使用
CN106432161A (zh) * 2016-07-19 2017-02-22 四川大学 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
CN107669689B (zh) * 2017-11-07 2021-04-30 浙江大学 一种治疗慢性阻塞性肺病的气雾剂
CN109350620B (zh) * 2018-12-15 2019-08-06 谭志军 一种治疗卵巢癌的药物及其用途
CN109498617A (zh) * 2018-12-26 2019-03-22 南京中医药大学 藁本内酯在制备防治骨质疏松症药品中的应用
CN111617071B (zh) * 2019-02-27 2023-05-23 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物
CN109966288A (zh) * 2019-05-05 2019-07-05 嘉兴市第二医院 一种治疗或预防动脉粥样硬化药物及应用
CN110169965B (zh) * 2019-05-28 2021-10-08 江苏康缘药业股份有限公司 一种化合物在治疗软骨退变性疾病方面的应用
CN114209691A (zh) * 2022-01-06 2022-03-22 正大青春宝药业有限公司 一种洋川芎内酯i复合物及在治疗心肌肥大疾病中的应用
CN118324730A (zh) * 2023-01-12 2024-07-12 陕西中医药大学 苯酞类化合物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6450818A (en) * 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
JPH01199958A (ja) * 1987-07-23 1989-08-11 Tsumura & Co 新規なフタリド誘導体およびその製造方法
JPH01207233A (ja) * 1988-02-12 1989-08-21 Tsumura & Co 抗動脈硬化症剤
JPH0477480A (ja) * 1990-07-19 1992-03-11 Tsumura & Co フタリド誘導体
WO1995000157A1 (fr) * 1993-06-25 1995-01-05 Mobius Consultancy Pty. Ltd. Agent therapeutique
WO2002022621A2 (fr) * 2000-09-14 2002-03-21 Allergan Inc. Oxazoles interphenylene 7-oxabicyclic[2.2.1]heptane en tant qu'antagonistes de la prostaglandin f¿2$g(a)?
CN1543859A (zh) * 2003-11-25 2004-11-10 中国人民解放军第二军医大学 藁本内酯用于防治动脉粥样硬化的用途
WO2004100945A1 (fr) * 2003-05-14 2004-11-25 Dsm Ip Assets B.V. Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
CN1569848A (zh) * 2003-07-14 2005-01-26 中国中医研究院中药研究所 治疗缺血性心脏病的川芎内酯及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500233A2 (fr) 1991-02-14 1992-08-26 National Semiconductor Corporation Structure de transistor bipolaire et méthode de fabrication BICMOS IC
CA2415742A1 (fr) * 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01199958A (ja) * 1987-07-23 1989-08-11 Tsumura & Co 新規なフタリド誘導体およびその製造方法
JPS6450818A (en) * 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
JPH01207233A (ja) * 1988-02-12 1989-08-21 Tsumura & Co 抗動脈硬化症剤
JPH0477480A (ja) * 1990-07-19 1992-03-11 Tsumura & Co フタリド誘導体
WO1995000157A1 (fr) * 1993-06-25 1995-01-05 Mobius Consultancy Pty. Ltd. Agent therapeutique
WO2002022621A2 (fr) * 2000-09-14 2002-03-21 Allergan Inc. Oxazoles interphenylene 7-oxabicyclic[2.2.1]heptane en tant qu'antagonistes de la prostaglandin f¿2$g(a)?
WO2004100945A1 (fr) * 2003-05-14 2004-11-25 Dsm Ip Assets B.V. Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
CN1569848A (zh) * 2003-07-14 2005-01-26 中国中医研究院中药研究所 治疗缺血性心脏病的川芎内酯及其制备方法
CN1543859A (zh) * 2003-11-25 2004-11-10 中国人民解放军第二军医大学 藁本内酯用于防治动脉粥样硬化的用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198938, Derwent World Patents Index; AN 1989-274524, XP002402180 *
DATABASE WPI Week 198939, Derwent World Patents Index; AN 1989-282536, XP002402179 *
DATABASE WPI Week 199217, Derwent World Patents Index; AN 1992-136751, XP002402181 *
DATABASE WPI Week 200517, Derwent World Patents Index; AN 2005-152885, XP002402178 *
DATABASE WPI Week 200577, Derwent World Patents Index; AN 2005-749412, XP002402177 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 238 (C - 603) 5 June 1989 (1989-06-05) *

Also Published As

Publication number Publication date
ATE529107T1 (de) 2011-11-15
CN101184484B (zh) 2011-10-05
WO2006125651A2 (fr) 2006-11-30
CN101184484A (zh) 2008-05-21
US20100298427A1 (en) 2010-11-25
KR20080015802A (ko) 2008-02-20
EP1937250B1 (fr) 2011-10-19
EP1937250A2 (fr) 2008-07-02
JP2008542226A (ja) 2008-11-27
US20090176873A1 (en) 2009-07-09
ES2375302T3 (es) 2012-02-28

Similar Documents

Publication Publication Date Title
WO2006125651A3 (fr) Nouvelle utilisation de composes organiques
WO2007120647A3 (fr) Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2003028641A3 (fr) Antagonistes du recepteur de la mch
WO2004013120A8 (fr) Nouveaux benzodioxoles
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
EP2221052A3 (fr) Compositions pour modulation de l'inflammation
WO2006011050A3 (fr) Derives de pyridine
WO2008011392A3 (fr) Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation
NO20081593L (no) Depotsammensetning
WO2005116002A3 (fr) Inhibiteurs de deshydrogenase 1-beta-hydroxy steroide de type 1
WO2007140439A3 (fr) Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
AU2003228674A1 (en) Muscarinic antagonists
DE602004011394D1 (en) Thiazolderivate
DK1765816T3 (da) Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande
WO2007146349A3 (fr) Antagonistes du récepteur du cgrp
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
WO2005115392A3 (fr) 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides utilises comme modulateurs des recepteurs de la chimiokine
WO2007079163A3 (fr) Antagonistes du recepteur de la prokineticine 1
BR0012696A (pt) Composição oftálmica
BR0215032A (pt) Composição herbicidamente ativa, método para controlar vegetação indesejável, e, uso de composições
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
WO2005075450A3 (fr) Nouveaux composes spiro-pentacycliques
TW200733878A (en) Polyalkoxylate-comprising solid plant protection compositions, processes for their preparation and their use
WO2007127027A3 (fr) Formulations à efficacité de nettoyage inattendue contenant un chélateur biodégradable

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753874

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 8512/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077027212

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680018241.2

Country of ref document: CN

Ref document number: 2008512773

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006753874

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11920346

Country of ref document: US